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Abstract
AIM: To evaluate the prognostic value of pretreatment 
FDG positron emission tomography computed 
tomography (PET-CT) in patients with hepatocarcinoma 
treated by liver transplantation (LT). 
METHODS: The authors retrospectively analyzed 
the data of 27 patients (mean age 58 ± 9 years) who 
underwent FDG PET-CT before LT for hepatocarcinoma. 
Mean follow-up was 26 ± 18 mo. The FDG PET/CT was 
performed according to a standard clinical protocol: 
4 MBqFDG/kg body weight, uptake 60 min, low-dose 
non-enhanced CT. The authors measured the SUVmax 
and SUVmean of the tumor and the normal liver. The 
tumor/liver activity ratios (RSUVmax and RSUVmean) 
were tested as prognostic factors and compared to 
the following conventional prognostic factors: MILAN, 
CLIP, OKUDA, TNM stage, alphafoetoprotein level, 
portal thrombosis, size of the largest nodule, tumor 
differentiation, microvascular invasion, underlying 
cirrhosis and liver function. 
RESULTS: Overall and recurrence free survivals were 
80.7% and 67.4% at 3 years, and 70.6% and 67.4% 
at 5 years, respectively. According to a multivariate 
Cox model, only FDG PET/CT RSUVmax predicted 
recurrence free survival. Even though the MILAN 
criteria alone were not predictive, it is worth noting that 
none of the patients outside the MILAN criteria and 
with RSUVmax < 1.15 relapsed. 
CONCLUSION: FDG PET/CT with an RSUVmax cut-
off value of 1.15 is a strong prognostic factor for 
recurrence and death in patients with HCC treated 
by LT in this retrospective series. Further prospective 
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However, it is clear that size and number of tumor 
nodules are not sufficient to precisely predict the risk of 
post LT HCC recurrence, and that the aggressiveness 
or differentiation of HCC should be taken into 
consideration. Microvascular invasion, AFP levels[6], and 
recently captation of 18F-fluorodeoxyglucose (18FDG) at 
positron emission tomography (PET)[7,8] have all been 
proposed to evaluate the biological staging of HCC.
At the University of Liege LT program, 18FDG- PET/ 
computed tomography (CT) has been introduced 
in the pretransplant evaluation of LT candidates 
suffering from HCC. The objective of this study was to 
retrospectively analyze the value of 18FDG- PET/CT in 
predicting post-LT recurrence of HCC by comparison 
with other prognostic factors.
MATERIALS AND METHODS
This study is a retrospective evaluation of the 52 
patients suffering from HCC and transplanted at 
the University of Liege hospital transplantation 
center between January 2006 and December 2011. 
Amongst these patients, 41 underwent 18FDG- PET/ 
CT evaluation before transplantation. Five patients 
were excluded as they had a past history of unrelated 
neoplasia, five others as they had undergone neo-
adjuvant therapy (mainly chemoembolization) prior 
to 18FDG- PET/ CT, 3 patients were lost to follow-up, 
and in one patient pathology of the explanted liver 
showed total tumoral necrosis. Twenty-seven patients 
were therefoe available for complete retrospective 
evaluation and their basic characteristics are presented 
in Table 1. Amongst the 27 patients, 13 suffered from 
HCC within the Milan criteria according to radiology 
and were granted standard exception (SE) status 
within the patient-oriented Eurotransplant liver graft 
allocation, and 14 were classified outside Milan criteria 
and received their liver graft in a centre-oriented 
rescue allocation[9]. Nine patients underwent neo-
adjuvant chemoembolization between PET/CT and LT. 
After transplant, basic immunosuppression consisted of 
regular triple therapy using tacrolimus, mycophenolate 
mofetil, and steroids that were progressively 
withdrawn after 4 wk. 
Collected clinical data included age, gender, viral 
status, Child-Turcotte-Pugh classification, tumor stage, 
tumor number, preoperative alphafoetoprotein (AFP) 
levels, the Okuda score[10], the Cancer of the Liver 
Italian Program (CLIP) score[11], histological grade, 
vascular invasion, recurrence and date of recurrence, 
and survival. Data are presented as mean ± SD and 
ranges. Median post transplantation follow-up was 732 
d (range: 37-2016 d). Mean interval between 18FDG- 
PET/ CT evaluation and LT was 77 d (range: 7-363 d).
18FDG- PET/ low-dose CT were performed in a 
standard manner using Gemini TF 16 and Gemini Big 
Bore scanners (Philips, Amsterdam, The Netherlands). 
Patients were fasted at least 6 h before injection of 
4 MBq/kg of 18FDG. Patients’ glycaemia was checked 
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studies should test whether this metabolic index 
should be systematically included in the preoperative 
assessment.
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Core tip: Patients suffering from hepatocarcinoma are 
selected for liver transplantation (LT) according to the 
Milan criteria that were established two decades ago. 
The aggressiveness of the tumor has also a particular 
importance, but there is still no ideal way of predicting 
the risk of recurrence according to pretransplant tumor 
metabolism. This study confirms that FDG positron 
emission tomography computed tomography with a 
tumor/liver activity ratios (RSUVmax) cut-off value of 
1.15 is a strong prognostic factor for recurrence and 
death in patients with hepatocellular cancer (HCC) 
treated by LT. In addition, in this series, none of the 
patients outside the MILAN criteria with RSUVmax 
< 1.15 suffered from recurrence in the follow-up. 
Further prospective studies should test whether this 
metabolic index should be systematically included in 
the pretransplant assessment of HCC patients.
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PET/CT in liver transplantation for hepatocarcinoma. World J 
Gastroenterol 2015; 21(10): 3049-3054  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i10/3049.htm  DOI: 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer, and the third cause of cancer 
related-death worldwide. HCC incidence is particularly 
elevated in regions where hepatitis-B virus infection 
is endemic[1], but is also rising in Western countries[2]. 
Liver transplantation (LT) has been established as the 
standard of care in selected candidates with underlying 
cirrhosis. However, the scarcity of organ donors has 
forced the development of strict criteria to limit LT to 
patients who are likely to have excellent outcomes. 
The universally accepted LT criteria for HCC are the 
Milan criteria (1 nodule ≤ 5 cm or 3 nodules ≤ 3 cm) 
that lead to a very low rate of post-LT recurrence[3], 
but many patients suffers from HCC outside the Milan 
criteria at the time of diagnosis. It is considered that 
some of these patients may benefit from LT with an 
acceptable risk of recurrence. This fact leads to the 
extension of LT criteria for HCC, as in the University 
of California San Francisco (UCSF)[4] criteria or up-to-
seven criteria[5].
and lower than 140 mg/dL before 18FDG injection, and 
they received 500 mL NaCl 0.9% intravenously after 
18FDG injection and before image acquisition. Static 
emission scanning was performed 60 min after 18FDG 
injection. The 18FDG- PET/CT images were first visually 
analyzed, then were semi-quantitatively evaluated to 
assess whether the 18FDG uptake in the tumor was 
significantly higher than the surrounding hepatic tissue. 
Regions of interest (ROI) were drawn over the normal 
liver and the tumor, and the standardized uptake 
values (SUV) in each ROI was measured. The ROI was 
drawn to encircle the highest activity of each tumor, 
with guidance from the CT scans that were acquired 
from PET/CT. The maximum SUV (SUVmax), the mean 
SUV (SUVmean), the ratio of tumor SUVmax to normal 
liver SUVmax (TSUVmax/LSUVmax), and the ratio of 
tumor SUVmax to normal liver SUVmean (TSUVmax/ 
LSUVmean) were calculated as described[12]. 
Statistical analysis
Data were analysed using the Prism 6.0c software 
for Macintosh OSX (GraphPad Software, San Diego, 
CA). Mean values ± SD and ranges are presented. 
A receiver operating curve (ROC) analysis was 
performed in order to define the optimal cut-off for the 
metabolic variables to predict the outcome. Survival 
rates were calculated with the Kaplan-Meier method 
and compared with the log-rank (Mantel-Cox) test. 
Parameters being predictive for global survival and 
recurrence-free survival were assessed in a univariate 
analysis. All variables with a P value less than 0.05 
were then included in a multivariate analysis applying 
the Cox multiple backward stepwise model to identify 
parameters being independently predictive. A value of 
P < 0.05 was considered significant. 
RESULTS
Patients’ characteristics
The characteristics of the 27 patients are presented 
in Table 1. The majority of patients were male, older 
than 50 years-of-age, and suffering from viral or 
post-alcoholic cirrhosis. Amongst patients with viral 
cirrhosis, 8 had past hepatitis B virus infection, 7 
hepatitis C virus related liver disease and one had 
both.
Global and recurrence free survivals
During the follow-up period, 5 patients developed 
HCC recurrence and 6 patients died. Within the 
whole series, one-, three- and five-year global 
patient survivals were 85.2%, 80.7% and 70.6%, 
respectively. One-, three- and five-year recurrence-
free survivals were 77.4%, 67.4% and 67.4%, 
respectively (Figure 1). When comparing recurrence-
free survivals according to 18FDG intake, there was 
a significant difference between 18FDG avid HCC 
compared to non-avid tumors P < 0.001) (Figure 2). 
The ROC curve analysis showed that 1.15 was the 
optimal cut-off value for predicting tumor recurrence, 
using the tumor to liver SUVmax activity ratios (Figure 
3). When considering combination of the Milan criteria 
and 18FDG, there was a significantly worse survival rate 
for patients transplanted for 18FDG avid HCC outside 
the Milan criteria (Figure 4) compared to the other 
groups of patients (P < 0.001), with 0% recurrence-
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Table 1  Patients characteristics (n  = 27)
Characteristics mean ± SD or n Ranges










AFP at transplant 
(ng/mL)
199 ± 476 0.9-1957








Number of nodules 1/2/3/> 3 5/6/3/13
Size of largest lesion 
(cm)
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Figure 1  Global and recurrence-free survivals (P = 0.52).
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DISCUSSION
This retrospective study confirms that 18FDG- PET 
with a TSUVmax/LSUVmax cut-off of 1.15 could be 
used as a selection criteria in the setting of LT for 
HCC. Particularly, HCC with a 18FDG RSUVmax < 1.15 
uptake seem to have a low risk of recurrence after 
LT. It is therefore possible that 18FDG-PET could be 
free survival at 2 years. Interestingly, there was no 
difference of recurrence-free survival between patients 
with HCC within the Milan criteria and the patients 
outside Milan criteria but who had 18FDG negative HCC 
(P = 0.782) (Figure 5).
Comparison between 18FDG PET/CT and other 
prognostic factors
According to univariate analysis, TSUVmax/LSUVmax, 
TSUVmean/ LSUVmean were prognostic factors for 
survival without HCC recurrence, and TSUVmax/
LSUVmax, TSUVmean/ LSUVmean, the size of the 
largest nodule, and the CLIP classification were 
prognostic factors for global survival in this series (Table 
2). According to multivariate analysis, only TSUVmax/
LSUVmax was a prognostic factor for survival without 
HCC recurrence (HR = 14.38; P = 0.0176).
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Figure 2  Recurrence-free survival curves according to 18F-fluorodeoxy-
glucose-positron emission tomography intake with a cut-off at 1.15 (P = 
0.0004).
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Figure 3  Receiver operating curve for recurrence. ROC: Receiver operating 
curve.
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Figure 4  Recurrence-free survival curves according to Milan criteria 
combined with 18F-fluorodeoxyglucose-positron emission tomography 
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Figure 5  Recurrence-free survival curves comparing Milan in (PET- and 
PET+) and Milan out with 18F-fluorodeoxyglucose-PET intake lower than 
1.15 (P = 0.78).
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used as a means of enlarging the Milan criteria for 
LT, allowing transplantation of HCC patients outside 
the Milan criteria but with an 18FDG RSUVmax < 1.15 
uptake with good chances of long term recurrence free 
survival.
The standard care for curative management of 
HCC in Western countries remains surgical resection 
and/or LT. Compared to hepatectomy, LT has two 
major advantages: first LT is possible in patients 
with impaired liver function that would not withstand 
liver resection, and second, as LT removes the 
whole cirrhotic liver, it avoids the main cause of HCC 
recurrence i.e., the development of a second HCC 
within the diseased liver. However, LT availability is 
limited by the number of available (deceased or living) 
grafts[13], and LT carries a high risk of recurrence 
and death if the HCC is not limited to the removed 
diseased liver. For these reasons, prognostic criteria 
for long-term recurrence-free survival after LT have 
been evaluated for more than 30 years. Up to now, 
the Milan criteria have still been universally used as 
the best criteria for recurrence-free survival after LT 
for HCC, but these criteria are not ideal. Firstly, the 
Milan criteria are pretransplant radiologic criteria that 
were evaluated more than two decades ago, and 
liver imaging and particularly MRI are now revealing 
hypervascularized nodules that could not be detected 
at the time of the Milan study. In addition, the Milan 
criteria are very restrictive and a small proportion 
of patients with HCC are diagnosed within the Milan 
criteria; finally, it is now clear that the size and number 
of HCC nodules are not the only prognostic factors for 
recurrence, and that somehow the aggressiveness 
of tumors should be taken into account. Tumor 
differentiation and AFP levels are now evaluated 
as markers of tumor aggressiveness, and AFP is 
included in the liver graft allocation scheme in France. 
Differentiation is difficult to use clinically, as not all 
HCC are biopsied before LT, and that differentiation 
of HCC may vary between tumoral nodules, or even 
within the same nodule. In this setting, 18FDG-PET 
could be a useful non-invasive pretransplant tool that 
could evaluate the metabolism and the aggressiveness 
of the primary HCC tumor, and could also detect the 
extrahepatic spread of cancer[7,14,15]. 
This study confirms the experience of other groups 
evaluating the role of 18FDG-PET in the pretransplant 
evaluation of HCC patients. This series confirms that 
TSUVmax/LSUVmax cut-off of 1.15 is probably the 
best level that should be used to characterize HCC for 
LT. In addition, this series shows that patients with 
Milan out HCC with a 18FDG RSUVmax < 1.15 uptake 
could benefit from LT[16]. In our series, recurrence-free 
survival of Milan out/18FDG PET negative patients was 
not decreased compared to patients with Milan in HCC. 
If confirmed, this finding could be used as a means to 
enlarge LT indications for HCC, allowing LT for some 
Milan out patients. This series also shows that Milan 
out and 18FDG/PET positive HCC have a very poor 
prognosis after LT, as all patients suffering from these 
aggressive cancers died from early recurrence. Finally, 
we hypothesise patients with Milan in but 18FDG/PET 
positive HCC might be a particular group of high-risk 
patients who should benefit from neoadjuvant therapy.
The limitations of this study are multiple. This 
is a retrospective evaluation of patients who were 
selected for LT, and it is probable that a prospective 
intention-to-treat study would demonstrate more 
precisely the role of 18FDG-PET in the setting of LT 
for HCC. In addition, this series is rather small, and a 
larger group of patients might help to more accurately 
define if Milan in but 18FDG/PET positive HCC have 
a worse prognosis than Milan in 18FDG/PET negative 
HCC after transplantation. Finally, the 18FDG/PET 
should be compared to other criteria that extend the 
Milan criteria, as the UCSF criteria or the up-to-seven 
criteria.
In conclusion, this study confirms that 18FDG/PET 
could be an interesting tool in the pre-LT evaluation of 
HCC patients and that the TSUVmax/LSUVmax cut-off 
of 1.15 should be used as a means to characterize 
HCC. Particularly, it deserves to be evaluated in a large 
prospective study if patients with HCC outside Milan 
criteria but with negative 18FDG PET, could be at low 
risk of recurrence after LT. 
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Background
Liver transplantation (LT) is the standard treatment of patients suffering from 
cirrhosis complicated with hepatocarcinoma (HCC), a cancer whose incidence 
is increasing. However, LT is usually applied to patients with small HCC 
corresponding to the so-called Milan criteria (one nodule ≤ 5 cm, ≤ 3 nodules 
≤ 3 cm). However, the Milan criteria are very restrictive and only a small 
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Table 2  Univariate comparison of prognostic factors
Recurrence free survival Global survival
HR P value HR P value
TSUVmax/LSUVmax > 
1.15
14.4 0.01 5.62 0.04
TSUVmean/LSUVmean 
> 1.15
14.4 0.01 5.62 0.04
Pretransplant treatment 1.01 0.99 0.32 0.30
AFP 0.99 0.47 1.00 0.52
Milan 3.97 0.21 1.97 0.43
Portal vein thrombosis 5.56 0.06 0.13 0.14
TNM (7th) 1.93 0.36 1.93 0.30
Differentiation
Low grade 20.3 0.05 12.4 0.08
Intermediate grade 2.37 0.46 2.78 0.37
High grade 1.00
Number of nodules > 107 0.99 > 107 0.99
Size of the largest nodule 1.29 0.05 1.33   0.009
Microvascular invasion 3.32 0.19 1.88 0.44
OKUDA 1.54 0.51 2.92 0.09
CLIP 1.26 0.60 2.39 0.03
AFP: Alphafoetoprotein; CLIP: Cancer of the liver italian program.
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might benefit of LT. Other factors than size are needed to determine if some 
patients outside the Milan criteria could benefit from LT. 
Research frontiers
18F-fluorodeoxyglucose/positron emission tomography (18FDG/PET) is a very 
useful tool in the management of many cancers. The role of 18FDG/PET in 
HCC is not established yet, particularly in HCC patients who could benefit from 
LT. Some groups advocated that 18FDG/PET could help to differentiate HCC 
patients with low or high risk of recurrence after transplantation.
Innovations and breakthroughs
This retrospective study confirms that patients with HCC outside the Milan 
criteria that have a low intake at 18FDG/PET might be good candidates for LT 
with a low risk of cancer recurrence.
Applications
This finding has to be confirmed by prospective studies that should 
prospectively determine if patients with HCC outside Milan criteria that do not 
have an intake at 18FDG/PET should be candidate for LT.
Terminology
Hepatocarcinoma is the primary cancer of the liver that often complicates a 
chronic liver disease named cirrhosis. 18FDG/PET is non invasive medical exam 
that allows a better evaluation of cancer metabolism and evolution. 
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